Put companies on watchlist
Alzchem Group AG
ISIN: DE000A2YNT30
WKN: A2YNT3
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Alzchem Group AG · ISIN: DE000A2YNT30 · EQS - Company News (77 News)
Country: Germany · Primary market: Germany · EQS NID: 1345223
05 May 2022 04:09PM

Annual General Meeting 2022 of Alzchem Group AG: Broad shareholder approval for growth course and dividend increase


DGAP-News: Alzchem Group AG / Key word(s): AGM/EGM
Annual General Meeting 2022 of Alzchem Group AG: Broad shareholder approval for growth course and dividend increase

05.05.2022 / 16:09
The issuer is solely responsible for the content of this announcement.


Annual General Meeting 2022 of Alzchem Group AG: Broad shareholder approval for growth course and dividend increase

Trostberg, 5 May 2022 – Today’s virtual Annual General Meeting of Alzchem Group AG expressed its continued confidence in the Management Board and the Supervisory Board by discharging them for the fiscal year 2021 and approved all agenda items with a large majority. In particular, an increase in the dividend from EUR 0.77 to EUR 1.00 per share (total distribution of approximately EUR 10.1 million) was approved. The increased payout of approximately EUR 2.3 million reflects the very successful fiscal year 2021 with new record levels of sales, EBITDA and net income. The proposed resolutions on the election of the auditor of the annual financial statements and the consolidated financial statements, the approval of the remuneration report and the creation of new authorized capital also received strong approval from the virtual plenum.

“We are grateful for the broad approval of the Annual General Meeting, as it once again represents a great vote of confidence in our work and strategy. At the same time, we also see it as a great incentive for the further successful development of Alzchem Group AG. We are particularly pleased for our shareholders that as a growth company we can continue to combine our ambitious plans with a reliable dividend strategy,” explains Andreas Niedermaier, CEO of Alzchem Group AG. “The fact that we were able to achieve several best performances in 2021 makes us just as confident for the future as the successful start to the fiscal year 2022 with a new record in quarterly sales as well as EBITDA slightly above the previous year’s level. After all, we have achieved all this together with our team of employees despite the current geopolitical situation, the disruptions in global logistics chains, and the extreme rise in raw material and energy prices. We continue to see ourselves on a good path to develop our businesses forward and achieve the goals we have set.”

The detailed voting results for the individual agenda items at the Annual General Meeting can be downloaded from the website at https://www.alzchem.com/en/investor-relations/annual-general-meeting/.

About Alzchem
Alzchem is a globally active specialty chemicals company that is predominantly among the market leaders in its fields of activity. Alzchem benefits in particular from the three very different global developments of climate change, population growth and longer life expectancy. In order to achieve the resulting social goals, Alzchem products can offer attractive solutions with a wide range of different applications.

The company sees interesting growth prospects for itself especially in the areas of human and animal nutrition and agriculture. As a result of population growth, it is necessary to achieve efficient food production. Pharmaceutical raw materials and our creatine products can contribute to healthy aging as life expectancy increases. Alzchem is facing up to the goal of sustainability arising from climate change in the field of renewable energies and across the entire company. The fields of fine chemicals and metallurgy offer just as great a perspective.

The broad product range of Alzchem Group AG includes dietary supplements, precursors for corona tests and pharmaceutical raw materials. These products are our company’s response to global trends and developments. Alzchem is ideally positioned in this regard and sees itself as well equipped for an environmentally oriented future and global developments.

The company employs around 1,630 people at four production sites in Germany and one plant in Sweden, as well as two sales companies in the USA and China. In 2021, Alzchem generated consolidated sales of around EUR 422.3 million and EBITDA of around EUR 62.0 million.



05.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Alzchem Group AG
Dr.-Albert-Frank-Str. 32
83308 Trostberg
Germany
Phone: +498621862888
Fax: +49862186502888
E-mail: ir@alzchem.com
Internet: www.alzchem.com
ISIN: DE000A2YNT30
WKN: A2YNT3
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Stuttgart
EQS News ID: 1345223

 
End of News DGAP News Service

1345223  05.05.2022 

fncls.ssp?fn=show_t_gif&application_id=1345223&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Alzchem Group AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.